COPD

AstraZeneca caps milestone week with FDA nod, COPD data

AstraZeneca secured accelerated FDA approval for its breast cancer drug Etcamah (camizestrant), capping a week of clinical milestones for the British-Swedish drugmaker that included positive late-stage data for a COPD treatment it expects could generate more than $5 billion in…

AstraZeneca’s COPD drug posts strong Phase 3 results, boosting blockbuster hopes

AstraZeneca on Tuesday released full results from two late-stage trials showing its experimental drug tozorakimab reduced dangerous flare-ups in a broad population of patients with chronic obstructive pulmonary disease, reinforcing the company's projection of more than $5 billion in peak…

You're all caught up

You've seen all the main stories from the past 2 days.